E7820 (splicing factor inhibitor)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-06-17 — A Study of E7820 in People With Bone Marrow (Myeloid) Cancers: Early-phase clinical trial launched evaluating E7820 in relapsed/refractory myeloid malignancies (AML, MDS, CMML) harboring splicing factor gene mutations (e.g., SF3B1, SRSF2, U2AF1), representing a synthetic-lethal approach targeting spliceosome-mutant clones. (novelty: 3)
Open questions
Related
Contributing findings
A Study of E7820 in People With Bone Marrow (Myeloid) Cancers
17-jun-2026
novelty 3
per-area 3
introduces